Inhibition of Azoxymethane-Induced Preneoplastic Lesions in the Rat Colon by a Cooked Stearic Acid Complexed High-Amylose Cornstarch
Yinsheng Zhao, Jovin Hasjim, Li Li, Jay‐lin Jane, Suzanne Hendrich, Diane F. Birt
Journal of Agricultural and Food Chemistry
Abstract
This study evaluated a novel stearic acid complexed high-amylose cornstarch (SAC) for the prevention of preneoplastic lesions in the colon of azoxymethane (AOM)-treated Fisher 344 rats fed resistant starches at 50-55% of the diet for 8 weeks. Uncooked SAC (r-SAC) diet was compared with raw normal-cornstarch diet (r-CS) or raw high-amylose cornstarch diet (r-HA), and water-boiled CS (w-CS) was compared with w-HA and w-SAC, respectively. w-SAC markedly reduced mucin-depleted foci (MDF) numbers compared with w-HA or w-CS. r-HA significantly decreased aberrant crypt foci (ACF) numbers compared with r-CS or r-SAC. Increased cecum weight and decreased cecum pH were observed in the SAC or HA groups. The highest amounts of total or individual short-chain fatty acids (SCFAs) in cecum and of butyrate or propionate in feces were observed in the AOM-treated w-SAC group. This study revealed the effectiveness of a novel resistant starch in inhibiting colonic preneoplastic lesions and the importance of high-moisture cooking on the suppression of colon carcinogenesis by this resistant starch.
Extracted Claims
6 claims extracted from this paper into the knowledge graph
cooked stearic acid complexed high-amylose cornstarch (SAC) decreases cecum pH
“Increased cecum weight and decreased cecum pH were observed in the SAC or HA groups.”
raw high-amylose cornstarch (r-HA) decreases aberrant crypt foci (ACF) numbers
“r-HA significantly decreased aberrant crypt foci (ACF) numbers compared with r-CS or r-SAC.”
cooked stearic acid complexed high-amylose cornstarch (SAC) increases total or individual short-chain fatty acids (SCFAs) in cecum
“The highest amounts of total or individual short-chain fatty acids (SCFAs) in cecum and of butyrate or propionate in feces were observed in the AOM-treated w-SAC group.”